Tracking of Glycans Structure and Metallomics Profiles in BRAF Mutated Melanoma Cells Treated with Vemurafenib

Nearly half of patients with advanced and metastatic melanomas harbor a mutation. Vemurafenib (VEM), a BRAF inhibitor, is used to treat such patients, however, responses to VEM are very short-lived due to intrinsic, adaptive and/or acquired resistance. In this context, we present the action of the B...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2021-01, Vol.22 (1), p.439
Hauptverfasser:	Nisiewicz, Monika K, Kowalczyk, Agata, Sobiepanek, Anna, Jagielska, Agata, Wagner, Barbara, Nowakowska, Julita, Gniadek, Marianna, Grudzinski, Ireneusz P, Kobiela, Tomasz, Nowicka, Anna M
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute phase proteins Binding sites Breast cancer Change detection Charge transfer Concanavalin A Concanavalin A - chemistry Concanavalin A - metabolism Enzyme inhibitors Experiments Glycoproteins Humans Kinases Lectins Melanoma Melanoma - drug therapy Melanoma - genetics Melanoma - metabolism Melanoma - pathology Metals - analysis Metals - metabolism Metastases Mutation Orosomucoid - chemistry Orosomucoid - metabolism Physiology Polysaccharides Polysaccharides - chemistry Protein kinase inhibitors Protein Kinase Inhibitors - pharmacology Proteins Proto-Oncogene Proteins B-raf - genetics Quartz crystal microbalance Skin cancer Spectrum analysis Ultrastructure Vemurafenib - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!